{"id":1998598,"date":"2023-08-12T06:55:02","date_gmt":"2023-08-12T10:55:02","guid":{"rendered":"https:\/\/www.conservativenewsdaily.net\/breaking-news\/wonderful-or-worrisome-what-to-know-about-new-weight-loss-drugs\/"},"modified":"2023-08-12T07:01:44","modified_gmt":"2023-08-12T11:01:44","slug":"wonderful-or-worrisome-what-to-know-about-new-weight-loss-drugs","status":"publish","type":"post","link":"https:\/\/www.conservativenewsdaily.net\/breaking-news\/wonderful-or-worrisome-what-to-know-about-new-weight-loss-drugs\/","title":{"rendered":"New weight loss drugs: Amazing or alarming? Essential information to consider."},"content":{"rendered":"<aside class=\"mashsb-container mashsb-main mashsb-stretched\"><div class=\"mashsb-box\"><div class=\"mashsb-count mash-medium\" style=\"float:left\"><div class=\"counts mashsbcount\">22<\/div><span class=\"mashsb-sharetext\">SHARES<\/span><\/div><div class=\"mashsb-buttons\"><a class=\"mashicon-facebook mash-medium mash-nomargin mashsb-noshadow\" href=\"https:\/\/www.facebook.com\/sharer.php?u=https%3A%2F%2Fwww.conservativenewsdaily.net%2Fbreaking-news%2Fwonderful-or-worrisome-what-to-know-about-new-weight-loss-drugs%2F\" target=\"_top\" rel=\"nofollow\"><span class=\"icon\"><\/span><span class=\"text\">Facebook<\/span><\/a><a class=\"mashicon-twitter mash-medium mash-nomargin mashsb-noshadow\" href=\"https:\/\/twitter.com\/intent\/tweet?text=&amp;url=https:\/\/www.conservativenewsdaily.net\/breaking-news\/?p=1998598&amp;via=ConservNewsDly\" target=\"_top\" rel=\"nofollow\"><span class=\"icon\"><\/span><span class=\"text\">Twitter<\/span><\/a><a class=\"mashicon-subscribe mash-medium mash-nomargin mashsb-noshadow\" href=\"#\" target=\"_top\" rel=\"nofollow\"><span class=\"icon\"><\/span><span class=\"text\">Subscribe<\/span><\/a><div class=\"onoffswitch2 mash-medium mashsb-noshadow\" style=\"display:none\"><\/div><\/div>\n            <\/div>\n                <div style=\"clear:both\"><\/div><\/aside>\n            <!-- Share buttons by mashshare.net - Version: 4.0.47--><h2>Pharmaceutical Giants \u200dCompete for Dominance\u200b in\u200b Weight Management Drug\u200d Market<\/h2>\n<p>Pharmaceutical giants Novo Nordisk and Eli Lilly are locked in a fierce\u200c competition \u200dto dominate the weight management drug\u200d market. Both companies have recently launched obesity\u2063 medications that \u2062have <a href=\"https:\/\/www.conservativenewsdaily.net\/breaking-news\/analyst-weighs-in-on-daniel-penny-chokehold-case\/\" title=\"Expert analyzes Daniel Penny's chokehold case.\">garnered significant attention<\/a>.<\/p>\n<h3>Novo\u2063 Nordisk&#8217;s \u2063Achievements \u2062and Challenges<\/h3>\n<p>Novo Nordisk has seen some setbacks with its \u2063weight management drug Wegovy and Type II diabetes medication Ozempic.\u200b These setbacks include production shortages\u200b and adverse patient\u2063 complications. However, the Danish company continues to grow its \u200bmarket \u200cshare and acquire \u2064smaller competitors.<\/p>\n<h3>Eli Lilly&#8217;s Strong Financial Growth<\/h3>\n<p>Eli Lilly, the maker of Type II diabetes\u2063 medication Mounjaro, has also <a href=\"https:\/\/www.conservativenewsdaily.net\/breaking-news\/wonderful-or-worrisome-what-to-know-about-new-weight-loss-drugs\/\" title=\"New weight loss drugs: Amazing or alarming? Essential information to consider.\">experienced strong financial growth<\/a> this quarter. The company is eagerly awaiting approval from \u200bthe\u200c Food and Drug \u200bAdministration to use Mounjaro as a <a href=\"https:\/\/www.conservativenewsdaily.net\/breaking-news\/doctors-say-these-are-the-four-most-effective-weight-loss-drugs\/\" title=\"Doctors Say These Are the Four Most Effective Weight-loss Drugs\">weight loss medication<\/a>, putting it in direct competition with Novo \u200bNordisk.<\/p>\n<h2>The Changing Landscape of Weight Management<\/h2>\n<p>Here is everything you need to know about\u2064 the changing\u200d weight management landscape.<\/p>\n<h3>How do these drugs work?<\/h3>\n<p>Ozempic \u200cand Wegovy both contain the active \u2064ingredient semaglutide, which functions as a \u2062GLP-1 agonist.\u200c This mimics the\u200b natural hormone that promotes insulin development in the body, leading to lower \u200cblood sugar levels.<\/p>\n<p>Ozempic was initially \u2064approved by the FDA as a once-weekly\u2063 injection medication for insulin-dependent Type II diabetes. While it is commonly prescribed as \u2062a <a href=\"https:\/\/www.conservativenewsdaily.net\/breaking-news\/overweight-cumin-spice-works-better-than-obesity-drugs\/\" title=\"Overweight? Cumin Spice Works Better Than Obesity Drugs\">weight loss drug<\/a>, it does not have FDA approval for that purpose. On\u200c the other hand, Wegovy, a higher \u2063dose of semaglutide \u200cthan Ozempic, received FDA approval \u200cas a weight loss medication \u2063in 2021.<\/p>\n<p>Mounjaro, also an injectable medication, was approved by \u2064the FDA in May 2022. It\u2064 treats diabetes differently\u200d than Ozempic \u2062by activating two different hormone receptors to stimulate \u200bnatural\u200b insulin production. While weight loss is a side effect of Mounjaro, it has not yet\u2062 received FDA clearance to be prescribed solely for weight management.<\/p>\n<h3>Effectiveness as\u200c Weight Loss Agents<\/h3>\n<p>Scientific evidence shows that these drugs are indeed effective as weight\u200b loss agents. One independent analysis found that patients taking GLP-1 \u2064agonists, including semaglutide, lost over 5% of their\u200c body \u200bweight. In fact, \u206350% \u2063of participants on semaglutide GLP-1 agonists \u200clost over 5% of their body\u2062 weight,\u200b making it\u2063 the most effective among the tested \u200cproducts.<\/p>\n<p>According to the FDA, <a href=\"https:\/\/www.conservativenewsdaily.net\/breaking-news\/aspirin-can-lower-risk-of-heart-disease-in-some-diabetic-patients\/\" title=\"Aspirin Can Lower Risk of Heart Disease in Some Diabetic Patients\">diabetic patients taking<\/a> the maximum dose of\u200c 15 milligrams of Mounjaro \u200dlost an average \u2064of \u200c15 pounds without insulin and 23 pounds with insulin. This is approximately\u200c 12 pounds\u2062 more on\u2062 average than \u2062the \u2062weight lost \u200bon semaglutide \u2064alone. Eli Lilly claims that Mounjaro can reduce body weight in diabetic \u200cpatients by 16%, or more\u2062 than 34 pounds,\u2064 in 17 \u2064months.<\/p>\n<p>However, \u2064patients who discontinue the medication are likely to regain the weight they lost.<\/p>\n<h3>Impact on Obesity Medicine<\/h3>\n<p>New research published \u200bin Nature Medicine found that obesity changes brain chemistry and the process of nutrient\u200d sensing. This supports the argument made by obesity medicine specialists and\u200b advocates that obesity\u200c should be\u2063 treated as a\u200b disease in itself.<\/p>\n<p>Novo Nordisk recently released data showing that \u2063Wegovy not\u200c only improves \u2062patient weight loss but\u200c also reduces heart attacks and strokes by 20%. This news \u2062has been encouraging for\u200d the Obesity Medicine \u200bAssociation, which believes that comprehensive \u2064treatment\u200b for obesity can \u200dimprove patients&#8217; overall health.<\/p>\n<h3>Possible Complications<\/h3>\n<p>There have \u200cbeen reports of gastrointestinal problems \u2064caused by GLP-1 agonists products \u2063for \u2064Type \u200dII diabetes. A lawsuit has been filed\u2063 against both Novo Nordisk and Eli Lilly, alleging that Ozempic\u200d and Mounjaro cause gastroparesis and gastroenteritis.\u2063 Mental health consequences are also being investigated in connection with GLP-1 agonists.<\/p>\n<h3>High Demand\u200b and its Effects<\/h3>\n<p>Both Novo Nordisk and Eli Lilly have experienced high demand \u200cfor their weight management drugs. Novo Nordisk expects higher sales in 2023, and Eli Lilly&#8217;s profits from Mounjaro have exceeded projections.<\/p>\n<p>Novo\u200b Nordisk\u200c has\u2064 faced challenges with manufacturing to meet the demand for semaglutide and injection pens. \u2062To address \u2064this, the company has limited the availability of starter doses for Wegovy and Ozempic to prioritize existing patients.<\/p>\n<p>Eli Lilly is building a new\u2062 manufacturing\u2063 plant in North\u2064 Carolina to address supply chain\u2064 challenges.<\/p>\n<h3>Impact on\u2062 the Healthcare\u200d Industry<\/h3>\n<p>Advocates for obesity medicine\u200b are\u2063 pushing for Wegovy to be covered by \u2062health insurance companies. The\u2063 recent data from the SELECT\u200b trial may help convince insurers\u2064 that Wegovy is a worthwhile preventive treatment for obesity.<\/p>\n<p>Legislation has also been introduced to \u200dcover obesity therapy treatments and medication, including Wegovy, under Medicare. Lawmakers recognize the \u2063need to combat the rising obesity rates and\u2063 make care more accessible.<\/p>\n<p>Novo Nordisk has hired a lobbying \u200cfirm to advocate for Medicare coverage\u200d of its\u2064 prime drug for weight\u2063 loss and \u200bobesity management.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Pharmaceutical giants Novo Nordisk and Eli Lilly fiercely compete for weight management drug market dominance. Novo Nordisk&#8217;s Wegovy and Ozempic face setbacks, but remain in the spotlight alongside Eli Lilly&#8217;s obesity medications.<\/p>\n","protected":false},"author":1,"featured_media":1998599,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_mo_disable_npp":"","fifu_image_url":"https:\/\/cndimages.nyc3.digitaloceanspaces.com\/breaking-news\/wp-content\/uploads\/2021\/01\/IMG_2758-scaled-1.jpg","fifu_image_alt":"","footnotes":""},"categories":[538],"tags":[],"class_list":["post-1998598","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-washington-examiner"],"fifu_image_url":"https:\/\/cndimages.nyc3.digitaloceanspaces.com\/breaking-news\/wp-content\/uploads\/2021\/01\/IMG_2758-scaled-1.jpg","_links":{"self":[{"href":"https:\/\/www.conservativenewsdaily.net\/breaking-news\/wp-json\/wp\/v2\/posts\/1998598","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.conservativenewsdaily.net\/breaking-news\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.conservativenewsdaily.net\/breaking-news\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.conservativenewsdaily.net\/breaking-news\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.conservativenewsdaily.net\/breaking-news\/wp-json\/wp\/v2\/comments?post=1998598"}],"version-history":[{"count":0,"href":"https:\/\/www.conservativenewsdaily.net\/breaking-news\/wp-json\/wp\/v2\/posts\/1998598\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.conservativenewsdaily.net\/breaking-news\/wp-json\/wp\/v2\/media\/1998599"}],"wp:attachment":[{"href":"https:\/\/www.conservativenewsdaily.net\/breaking-news\/wp-json\/wp\/v2\/media?parent=1998598"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.conservativenewsdaily.net\/breaking-news\/wp-json\/wp\/v2\/categories?post=1998598"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.conservativenewsdaily.net\/breaking-news\/wp-json\/wp\/v2\/tags?post=1998598"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}